Mink Therapeutics Inc
minktherapeutics.comWhat Do They Do?
Develops off-the-shelf cell therapies made from invariant natural killer T cells for cancer and immune-mediated diseases.
10-K for FY2025, filed Mar 31, 2026
Who Are Their Customers?
Physicians initiate requests for agenT-797 for individual patients through a paid access program, subject to case-by-case Brazilian regulatory authorization.
8-K, filed Aug 13, 2026
How Are They Changing?
-
Aug 13, 2026
MiNK begins paid international named-patient access for agenT-797
Physicians can request product for individual patients through a paid program, subject to Brazilian authorization.
Sources
8-K, filed Aug 13, 2026
First paid international access program established. MiNK is collaborating with Orphan Drug Consulting (ODC) to support physician-initiated…View ↗
Who Do They Compete With?
Competes with Bristol-Myers Squibb, Gilead Sciences, Johnson & Johnson, Novartis, AstraZeneca, BioNTech, Arovella Therapeutics, Brightpath Biotherapeutics, Gri Bio, Portage Biotech, Allogene Therapeutics, Atara Biotherapeutics, Cellectis, CRISPR Therapeutics, Precision BioSciences, Poseida Therapeutics, Fate Therapeutics, Nkarta, Artiva Biotherapeutics, and Dragonfly Therapeutics
10-K for FY2025, filed Mar 31, 2026Key competitors developing autologous CAR-T and TCR-based therapies include large pharmaceutical and biotechnology companies such as…View ↗
Loading...
